David Ryder

1.4k total citations
35 papers, 1.0k citations indexed

About

David Ryder is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, David Ryder has authored 35 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in David Ryder's work include Substance Abuse Treatment and Outcomes (10 papers), Mental Health Treatment and Access (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). David Ryder is often cited by papers focused on Substance Abuse Treatment and Outcomes (10 papers), Mental Health Treatment and Access (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). David Ryder collaborates with scholars based in United Kingdom, Australia and United States. David Ryder's co-authors include Alex Molassiotis, Peter Mackereth, Emma Ream, Alison Richardson, Jennifer Finnegan-John, Jacqueline Filshie, Myra F. Taylor, George Patton, John W. Toumbourou and Dennis Gray and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Addiction.

In The Last Decade

David Ryder

35 papers receiving 938 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Ryder United Kingdom 13 300 211 202 169 161 35 1.0k
Megan E. Miller United States 20 366 1.2× 219 1.0× 134 0.7× 203 1.2× 50 0.3× 79 1.3k
Ana Macedo Portugal 14 147 0.5× 129 0.6× 82 0.4× 116 0.7× 49 0.3× 68 985
Petra Rauchhaus United Kingdom 17 161 0.5× 98 0.5× 159 0.8× 73 0.4× 86 0.5× 37 1.5k
Karen Poole United Kingdom 15 410 1.4× 104 0.5× 80 0.4× 53 0.3× 61 0.4× 38 943
Marianne Steding‐Jessen Denmark 22 626 2.1× 181 0.9× 195 1.0× 70 0.4× 261 1.6× 38 1.3k
Robert P. Derhagopian United States 18 851 2.8× 225 1.1× 280 1.4× 363 2.1× 61 0.4× 28 1.7k
Judith Hurley United States 24 1.1k 3.6× 191 0.9× 150 0.7× 343 2.0× 87 0.5× 74 2.3k
Nicholas Hyde United Kingdom 13 467 1.6× 228 1.1× 148 0.7× 49 0.3× 40 0.2× 26 959
J. Davidson Canada 16 579 1.9× 351 1.7× 191 0.9× 54 0.3× 45 0.3× 29 1.4k
Helena Carreira United Kingdom 18 601 2.0× 187 0.9× 274 1.4× 73 0.4× 221 1.4× 42 1.2k

Countries citing papers authored by David Ryder

Since Specialization
Citations

This map shows the geographic impact of David Ryder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ryder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ryder more than expected).

Fields of papers citing papers by David Ryder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ryder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ryder. The network helps show where David Ryder may publish in the future.

Co-authorship network of co-authors of David Ryder

This figure shows the co-authorship network connecting the top 25 collaborators of David Ryder. A scholar is included among the top collaborators of David Ryder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ryder. David Ryder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ryder, David, et al.. (2023). Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study. Clinical and Translational Radiation Oncology. 40. 100614–100614. 7 indexed citations
2.
3.
4.
Yorke, Janelle, Miriam J. Johnson, John A. Smith, et al.. (2022). Respiratory distress symptom intervention for non-pharmacological management of the lung cancer breathlessness–cough–fatigue symptom cluster: randomised controlled trial. BMJ Supportive & Palliative Care. 13(e3). e1181–e1190. 11 indexed citations
5.
6.
McNamara, Mairéad G., John Bridgewater, Daniel H. Palmer, et al.. (2018). ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers.. Journal of Clinical Oncology. 36(4_suppl). TPS544–TPS544. 2 indexed citations
7.
Goddard, Perilou, et al.. (2017). Observations of the role of science in the United States medical cannabis state policies: Lessons learnt. International Journal of Drug Policy. 42. 109–114. 8 indexed citations
8.
Koh, P., Ben Taylor, Mahbubunnabi Tamal, et al.. (2014). Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. European Journal of Nuclear Medicine and Molecular Imaging. 41(4). 682–693. 36 indexed citations
9.
Eustace, Amanda, Joely J. Irlam, Janet Taylor, et al.. (2013). Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiotherapy and Oncology. 108(1). 40–47. 44 indexed citations
10.
Molassiotis, Alex, Jennifer Finnegan-John, Peter Mackereth, et al.. (2012). Acupuncture for Cancer-Related Fatigue in Patients With Breast Cancer: A Pragmatic Randomized Controlled Trial. Journal of Clinical Oncology. 30(36). 4470–4476. 184 indexed citations
11.
Gausia, Kaniz, Allisyn C. Moran, Mohammed Ali, et al.. (2011). Psychological and social consequences among mothers suffering from perinatal loss: perspective from a low income country. BMC Public Health. 11(1). 451–451. 48 indexed citations
12.
Silva, Priyamal, N.J. Slevin, Philip Sloan, et al.. (2008). Prognostic Significance of Tumor Hypoxia Inducible Factor–1α Expression for Outcome After Radiotherapy in Oropharyngeal Cancer. International Journal of Radiation Oncology*Biology*Physics. 72(5). 1551–1559. 43 indexed citations
13.
Ryder, David. (2008). Political and legal institutions and their influence on drug policy: an Australian perspective. Drug and Alcohol Review. 27(4). 374–379. 3 indexed citations
14.
Johnson, Peter, John Radford, Michael Cullen, et al.. (2005). Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Journal of Clinical Oncology. 23(36). 9208–9218. 95 indexed citations
15.
Ryder, David, et al.. (2001). Drug use and drug-related harm: a delicate balance.. 12 indexed citations
16.
Ryder, David. (1999). Deciding to Change: Enhancing Client Motivation to Change Behaviour. Behaviour Change. 16(3). 165–174. 8 indexed citations
17.
Ryder, David. (1996). Alcohol, casemix and hospitals: an opportunity?. Drug and Alcohol Review. 15(4). 415–419. 1 indexed citations
18.
Ryder, David. (1988). Minimal Intervention: A Little Quality for a Lot of Quantity?. Behaviour Change. 5(3). 100–107. 12 indexed citations
19.
Ryder, David. (1987). Surviving as a Controlled Drinking Therapist. 6(2). 153–156. 2 indexed citations
20.
Ryder, David. (1987). Secondary Prevention of Alcohol Related Problems. 6(4). 271–277. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Megan E. Miller Breakdown of academic impact, for papers by Ana Macedo Breakdown of academic impact, for papers by Petra Rauchhaus Breakdown of academic impact, for papers by Karen Poole Breakdown of academic impact, for papers by Marianne Steding‐Jessen Breakdown of academic impact, for papers by Robert P. Derhagopian Breakdown of academic impact, for papers by Judith Hurley Breakdown of academic impact, for papers by Nicholas Hyde Breakdown of academic impact, for papers by J. Davidson Breakdown of academic impact, for papers by Helena Carreira
Rankless by CCL
2026